Abstract
Pulmonary changes in thrombin formation in patients with acute lung injury or pneumonia are remarkably similar to systemic changes in coagulation observed in septic patients. Since anticoagulant therapy has proven to be successful in the treatment of patients with sepsis, the same therapeutic strategy may benefit patients with acute lung injury or pneumonia. Based on the fact that inflammation not only leads to dysregulation of the coagulation system, but vice versa, activation of coagulation amplifies inflammatory processes as well, it can be questioned whether the advantage of anticoagulant therapy is solely related to its influence on disturbed thrombin formation. In this paper we will discuss local changes in the haemostatic balance during acute lung injury, both in pre-clinical and clinical studies. Until now, pre-clinical studies have demonstrated that interventions aimed at correction of coagulation abnormalities may form an important strategy in patients with acute lung injury in the future. Pre-clinical studies on use of anticoagulants during pneumonia are presently performed and data are underway.
Keywords: coagulation, fibrinolysis, sepsis, acute lung injury, pneumonia, bronchoalveolar fluid, cytokines, thrombin, tissue factor
Current Drug Targets
Title: Anticoagulant Therapy for Acute Lung Injury or Pneumonia
Volume: 4 Issue: 4
Author(s): Marcus J. Schultz, Marcel Levi and Tom van der Poll
Affiliation:
Keywords: coagulation, fibrinolysis, sepsis, acute lung injury, pneumonia, bronchoalveolar fluid, cytokines, thrombin, tissue factor
Abstract: Pulmonary changes in thrombin formation in patients with acute lung injury or pneumonia are remarkably similar to systemic changes in coagulation observed in septic patients. Since anticoagulant therapy has proven to be successful in the treatment of patients with sepsis, the same therapeutic strategy may benefit patients with acute lung injury or pneumonia. Based on the fact that inflammation not only leads to dysregulation of the coagulation system, but vice versa, activation of coagulation amplifies inflammatory processes as well, it can be questioned whether the advantage of anticoagulant therapy is solely related to its influence on disturbed thrombin formation. In this paper we will discuss local changes in the haemostatic balance during acute lung injury, both in pre-clinical and clinical studies. Until now, pre-clinical studies have demonstrated that interventions aimed at correction of coagulation abnormalities may form an important strategy in patients with acute lung injury in the future. Pre-clinical studies on use of anticoagulants during pneumonia are presently performed and data are underway.
Export Options
About this article
Cite this article as:
Schultz J. Marcus, Levi Marcel and Poll van der Tom, Anticoagulant Therapy for Acute Lung Injury or Pneumonia, Current Drug Targets 2003; 4 (4) . https://dx.doi.org/10.2174/1389450033491064
DOI https://dx.doi.org/10.2174/1389450033491064 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Recognition and Impact of Host-derived Molecules on Bacterial Cell-tocell Signalling Pathways
Medicinal Chemistry Role of Nitric Oxide in Liver Injury
Current Molecular Medicine Sequence Analysis of Native Oligosaccharides Using Negative ESI Tandem MS
Current Analytical Chemistry Exploratory and Regulatory Assessments on Photosafety of New Drug Entities
Current Drug Safety Platelets and Vascular Risk: An Option for Treatment
Current Pharmaceutical Design Editorial (Thematic Issue):Inflammation and Atherosclerosis: The Role of Novel Biomarkers (Part-I)
Current Medicinal Chemistry Hematological Targets of Radiation Damage
Current Drug Targets Cisplatin Toxicology: The Role of Pro-inflammatory Cytokines and GABA Transporters in Cochlear Spiral Ganglion
Current Pharmaceutical Design Endometriosis and Perinatal Outcome - A Systematic Review of the Literature
Current Women`s Health Reviews Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets miR-122 is a Unique Molecule with Great Potential in Diagnosis, Prognosis of Liver Disease, and Therapy Both as miRNA Mimic and Antimir
Current Gene Therapy Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Alert Cell Strategy: Mechanisms of Inflammatory Response and Organ Protection
Current Pharmaceutical Design Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Selenium and Autoimmune Diseases: A Review Article
Current Rheumatology Reviews Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Pharmaceutical Interventions to Influence Arteriogenesis: New Concepts to Treat Ischemic Heart Disease
Current Medicinal Chemistry